LT5550B - Escitalopramo kristalinė bazė ir burnoje suyrančios tabletės, apimančios escitalopramo bazę - Google Patents

Escitalopramo kristalinė bazė ir burnoje suyrančios tabletės, apimančios escitalopramo bazę Download PDF

Info

Publication number: LT5550B
Authority: LT; Lithuania
Prior art keywords: escitalopram; base; free base; salt; crystalline
Prior art date: 2005-06-22

Application number

LT2008005A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT2008005A (en

Inventor

Robert Dancer

Hans Petersen

Ole Nielsen

Michael Harold Rock

Helle Eliasen

Ken Liljegren

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-22

Filing date

2008-01-21

Publication date

2009-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT5550(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-21 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2008-10-27 Publication of LT2008005A publication Critical patent/LT2008005A/xx

2009-03-25 Publication of LT5550B publication Critical patent/LT5550B/lt

Links

WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 title description 145
229960004341 escitalopram Drugs 0.000 title description 140
239000003826 tablet Substances 0.000 description 154
239000000203 mixture Substances 0.000 description 90
239000002585 base Substances 0.000 description 89
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 66
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 61
238000000034 method Methods 0.000 description 61
229930195725 Mannitol Natural products 0.000 description 54
239000000594 mannitol Substances 0.000 description 54
235000010355 mannitol Nutrition 0.000 description 54
239000012458 free base Substances 0.000 description 46
239000000945 filler Substances 0.000 description 39
230000008569 process Effects 0.000 description 37
229920000168 Microcrystalline cellulose Polymers 0.000 description 35
229940016286 microcrystalline cellulose Drugs 0.000 description 35
235000019813 microcrystalline cellulose Nutrition 0.000 description 35
239000008108 microcrystalline cellulose Substances 0.000 description 35
235000019359 magnesium stearate Nutrition 0.000 description 33
239000000546 pharmaceutical excipient Substances 0.000 description 33
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 31
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 30
238000007906 compression Methods 0.000 description 28
230000006835 compression Effects 0.000 description 28
238000002844 melting Methods 0.000 description 27
230000008018 melting Effects 0.000 description 27
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 23
239000007884 disintegrant Substances 0.000 description 22
150000003839 salts Chemical class 0.000 description 22
238000002425 crystallisation Methods 0.000 description 18
230000008025 crystallization Effects 0.000 description 18
239000008186 active pharmaceutical agent Substances 0.000 description 17
238000005054 agglomeration Methods 0.000 description 17
WIHMBLDNRMIGDW-BDQAORGHSA-N escitalopram hydrobromide Chemical compound Br.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WIHMBLDNRMIGDW-BDQAORGHSA-N 0.000 description 17
238000010438 heat treatment Methods 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 16
230000002776 aggregation Effects 0.000 description 16
239000012535 impurity Substances 0.000 description 16
239000000314 lubricant Substances 0.000 description 16
239000002245 particle Substances 0.000 description 16
KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 15
238000002156 mixing Methods 0.000 description 15
239000002904 solvent Substances 0.000 description 15
239000007787 solid Substances 0.000 description 14
239000011230 binding agent Substances 0.000 description 13
229940083542 sodium Drugs 0.000 description 13
235000015424 sodium Nutrition 0.000 description 13
239000011734 sodium Substances 0.000 description 13
229910052708 sodium Inorganic materials 0.000 description 13
229920003084 Avicel® PH-102 Polymers 0.000 description 12
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
229960005086 escitalopram oxalate Drugs 0.000 description 12
238000004128 high performance liquid chromatography Methods 0.000 description 12
239000008101 lactose Substances 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000013078 crystal Substances 0.000 description 11
238000000746 purification Methods 0.000 description 11
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 10
150000001875 compounds Chemical class 0.000 description 10
238000001556 precipitation Methods 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
229960000913 crospovidone Drugs 0.000 description 9
239000000155 melt Substances 0.000 description 9
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 9
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 9
229910000042 hydrogen bromide Inorganic materials 0.000 description 8
239000008194 pharmaceutical composition Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 7
239000012071 phase Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
239000004480 active ingredient Substances 0.000 description 6
238000001125 extrusion Methods 0.000 description 6
239000008187 granular material Substances 0.000 description 6
-1 mamnose Chemical compound 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
150000003891 oxalate salts Chemical class 0.000 description 6
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
229920002785 Croscarmellose sodium Polymers 0.000 description 5
229920003085 Kollidon® CL Polymers 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
229950008138 carmellose Drugs 0.000 description 5
229960005168 croscarmellose Drugs 0.000 description 5
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 5
238000001953 recrystallisation Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
DIOGFDCEWUUSBQ-FQEVSTJZSA-N 3-[(1s)-5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]-n,n-dimethylpropan-1-amine oxide Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCC[N+](C)([O-])C)=CC=C(F)C=C1 DIOGFDCEWUUSBQ-FQEVSTJZSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
238000013019 agitation Methods 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
229960001653 citalopram Drugs 0.000 description 4
238000000113 differential scanning calorimetry Methods 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical class 0.000 description 4
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 4
210000000214 mouth Anatomy 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
235000006408 oxalic acid Nutrition 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 3
CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
150000001204 N-oxides Chemical class 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
235000011114 ammonium hydroxide Nutrition 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
125000004093 cyano group Chemical group *C#N 0.000 description 3
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
229960002297 fenofibrate Drugs 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002955 isolation Methods 0.000 description 3
238000010907 mechanical stirring Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
238000010992 reflux Methods 0.000 description 3
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 2
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical group C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229960000673 dextrose monohydrate Drugs 0.000 description 2
238000007907 direct compression Methods 0.000 description 2
AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
238000005507 spraying Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
PTJADDMMFYXMMG-IBGZPJMESA-N (1s)-1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-3h-2-benzofuran-5-carbonitrile Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCNC)=CC=C(F)C=C1 PTJADDMMFYXMMG-IBGZPJMESA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
COAPWBUTTSOWLG-IBGZPJMESA-N 3-[(1s)-5-chloro-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]-n,n-dimethylpropan-1-amine Chemical compound C1([C@]2(C3=CC=C(Cl)C=C3CO2)CCCN(C)C)=CC=C(F)C=C1 COAPWBUTTSOWLG-IBGZPJMESA-N 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
JMRFFXXIKAWNQQ-UHFFFAOYSA-N 5-bromo-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran Chemical compound C1=CC(F)=CC=C1C1C2=CC=C(Br)C=C2CO1 JMRFFXXIKAWNQQ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
OEYZDGFROIIQRK-UHFFFAOYSA-N C1CCCCC1.CC(C)CC(C)(C)C Chemical compound C1CCCCC1.CC(C)CC(C)(C)C OEYZDGFROIIQRK-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229920003110 Primojel Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
CXOWYMLTGOFURZ-UHFFFAOYSA-N azanylidynechromium Chemical compound [Cr]#N CXOWYMLTGOFURZ-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000000872 buffer Substances 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 description 1
229960004587 carisoprodol Drugs 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
229960002563 disulfiram Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
229960002767 ethosuximide Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229960002146 guaifenesin Drugs 0.000 description 1
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
PKMNZOFQIRXQDO-UHFFFAOYSA-N heptane;hexane Chemical compound CCCCCC.CCCCCCC PKMNZOFQIRXQDO-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
238000007654 immersion Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000010884 ion-beam technique Methods 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
229940011051 isopropyl acetate Drugs 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
238000007909 melt granulation Methods 0.000 description 1
CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229960000762 perphenazine Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000011257 shell material Substances 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000008137 solubility enhancer Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
229960004453 trimethadione Drugs 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
238000010792 warming Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Furan Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

LT2008005A 2005-06-22 2008-01-21 Escitalopramo kristalinė bazė ir burnoje suyrančios tabletės, apimančios escitalopramo bazę LT5550B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA200500912		2005-06-22

Publications (2)

Publication Number	Publication Date
LT2008005A LT2008005A (en)	2008-10-27
LT5550B true LT5550B (lt)	2009-03-25

Family

ID=37546630

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT2008005A LT5550B (lt)	2005-06-22	2008-01-21	Escitalopramo kristalinė bazė ir burnoje suyrančios tabletės, apimančios escitalopramo bazę

Country Status (39)

Country	Link
EP (3)	EP2325177A1 (pt)
JP (5)	JP4906852B2 (pt)
KR (5)	KR101340815B1 (pt)
CN (2)	CN101928269A (pt)
AR (2)	AR055062A1 (pt)
AT (3)	AT10983U1 (pt)
AU (2)	AU2006261452B2 (pt)
BG (1)	BG66086B1 (pt)
BR (1)	BRPI0612295A2 (pt)
CA (2)	CA2612827C (pt)
CY (1)	CY1112392T1 (pt)
CZ (3)	CZ301286B6 (pt)
DE (2)	DE112006001619T5 (pt)
DK (3)	DK1896439T4 (pt)
EA (2)	EA201001108A1 (pt)
EE (1)	EE00773U1 (pt)
ES (2)	ES2356838T5 (pt)
FI (2)	FI20080548L (pt)
GB (2)	GB2448834B (pt)
HR (1)	HRP20110093T4 (pt)
HU (1)	HUP0800135A3 (pt)
IL (1)	IL187454A0 (pt)
IS (1)	IS8705A (pt)
LT (1)	LT5550B (pt)
LV (1)	LV13677B (pt)
MX (1)	MX2007015328A (pt)
MY (2)	MY143239A (pt)
NO (2)	NO20080359L (pt)
PL (2)	PL1896439T5 (pt)
PT (1)	PT1896439E (pt)
RS (1)	RS51575B2 (pt)
SG (1)	SG169358A1 (pt)
SI (1)	SI1896439T2 (pt)
SK (1)	SK500402007A3 (pt)
TR (2)	TR200708792T1 (pt)
TW (2)	TWI358407B (pt)
UA (1)	UA86536C2 (pt)
WO (1)	WO2006136169A2 (pt)
ZA (2)	ZA200711066B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0123400D0 (en)	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
WO2008059514A2 (en) *	2006-07-31	2008-05-22	Cadila Healthcare Limited	Process for preparing escitalopram
WO2008104880A2 (en) *	2007-03-01	2008-09-04	Aurobindo Pharma Limited	Stable solid dosage forms of an antidepressant
SI2595979T1 (sl)	2010-07-23	2016-09-30	H. Lundbeck A/S	Proces za čiščenje farmacevtsko sprejemljivih soli Escitaloprama
CN103360353A (zh) *	2013-08-07	2013-10-23	中国药科大学	草酸艾司西酞普兰杂质的制备方法
JP2018016569A (ja) *	2016-07-26	2018-02-01	株式会社トクヤマ	（１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
WO2018190294A1 (ja) *	2017-04-10	2018-10-18	東和薬品株式会社	エスシタロプラム医薬組成物
CN110711198B (zh) *	2018-07-12	2022-03-15	山东大学	D-甘露糖在制备抗抑郁药物中的应用
KR102331187B1 (ko)	2019-04-09	2021-11-26	주식회사 라이트팜텍	에스시탈로프람을 함유하는 안정성이 우수한 경구용 액제 조성물 및 그의 제조방법
US20240100012A1 (en) *	2021-01-18	2024-03-28	Mark Hasleton	Pharmaceutical dosage form

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4943590A (en)	1988-06-14	1990-07-24	H. Lundbeck A/S	Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof
WO2004056791A1 (en)	2002-12-23	2004-07-08	H. Lundbeck A/S	Escitalopram hydrobromide and a method for the preparation thereof
WO2005018617A1 (en)	2003-08-19	2005-03-03	Wyeth	Fast dissolving tablet

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1526331A (en)	1976-01-14	1978-09-27	Kefalas As	Phthalanes
JPH05222041A (ja) *	1992-02-13	1993-08-31	Mitsubishi Gas Chem Co Inc	アデニン誘導体の精製法
HUT74514A (en) *	1994-01-27	1997-01-28	Janssen Pharmaceutica Nv	Rapidly dissolving oral dosage form
US5607697A (en) *	1995-06-07	1997-03-04	Cima Labs, Incorporated	Taste masking microparticles for oral dosage forms
EP0993524B1 (en)	1997-06-30	2002-11-20	Beloit Technologies, Inc.	Method and apparatus for the high speed application of coating to a traveling paper web
JP3526581B2 (ja)	1997-07-08	2004-05-17	ハー・ルンドベック・アクティーゼルスカブ	シタロプラムの製造方法
CN1286687A (zh)	1997-11-11	2001-03-07	H·隆德贝克有限公司	制备西酞普兰的方法
FR2785538B1 (fr) *	1998-11-06	2004-04-09	Prographarm Laboratoires	Comprime a delitement rapide perfectionne
US20020071864A1 (en) *	1999-03-25	2002-06-13	Yuhan Corporation	Rapidly disintegrable tablet for oral administration
ITMI991581A1 (it) *	1999-06-25	2001-01-15	Lundbeck & Co As H	Metodo per la preparazione di citalopram
ITMI991579A1 (it)	1999-06-25	2001-01-15	Lundbeck & Co As H	Metodo per la preparazione di citalopram
JP2001226372A (ja) *	1999-12-06	2001-08-21	Sumika Fine Chemicals Co Ltd	ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
GB2357762B (en) *	2000-03-13	2002-01-30	Lundbeck & Co As H	Crystalline base of citalopram
US7510728B2 (en) *	2000-10-06	2009-03-31	Takeda Pharmaceutical Company Limited	Solid preparations
CN1469737A (zh) *	2000-10-16	2004-01-21	��һ��ҩ��ʽ��	口腔内快速崩解的药用组合物及其制备方法
TR200201166T1 (tr) *	2000-12-22	2002-10-21	H.Lundbecks A/S	Saf sitalopram hazırlanması için yöntem
JP2003519121A (ja) *	2000-12-28	2003-06-17	ハー・ルンドベック・アクチエゼルスカベット	純粋なシタロプラムの製造方法
CA2445843A1 (en) *	2001-05-01	2002-11-07	H. Lundbeck A/S	The use of enantiomeric pure escitalopram
US6872405B2 (en) *	2001-05-10	2005-03-29	Yamanouchi Pharmaceutical Co., Ltd.	Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
GB0113842D0 (en) *	2001-06-07	2001-08-01	Boots Co Plc	Therapeutic agents
AR034612A1 (es) *	2001-06-25	2004-03-03	Lundbeck & Co As H	Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es)	2001-07-13	2004-03-17	Lundbeck & Co As H	Metodo para la preparacion de escitalopram
ATE352546T1 (de) *	2001-07-31	2007-02-15	Lundbeck & Co As H	Kristalline zusammensetzung enthaltend escitalopram
IS7239A (is)	2001-12-14	2004-04-29	H. Lundbeck A/S	Aðferð til framleiðslu á essítalóprami
WO2003057132A2 (en) *	2002-01-07	2003-07-17	Sun Pharmaceutical Industries Limited	Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
FR2834889B1 (fr) *	2002-01-18	2004-04-02	Roquette Freres	Forme pharmaceutique solide orodispersible
GB0204607D0 (en) *	2002-02-27	2002-04-10	Matrix Lab Ltd	Process
WO2003092659A1 (en) *	2002-05-03	2003-11-13	Skyepharma Canada Inc.	Oral dosage forms comprising fenofibrate
CN1510024A (zh) *	2002-12-24	2004-07-07	北京德众万全药物技术开发有限公司	可用于制备西酞普兰(s)-对映异构体的新的化合物及其制备方法
DE10305984A1 (de) *	2003-02-13	2004-09-02	Helm Ag	Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
JP4739217B2 (ja) *	2003-05-07	2011-08-03	サムヤンコーポレイション	速く溶ける錠剤を製造するための高可塑性顆粒
IN234086B (pt) *	2003-10-15	2009-05-29	Fuji Chem Ind Co Ltd
AU2003282383A1 (en) *	2003-11-20	2005-06-08	Natco Pharma Limited	A process for the preparation of high purity escitalopram
HU227491B1 (en) *	2003-11-25	2011-07-28	Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag	Tablet containing citalopram hydrogen bromide
NZ549100A (en) *	2004-03-05	2010-02-26	Lundbeck & Co As H	Crystalline composition containing escitalopram oxalate
EP1877394A1 (en) *	2005-04-04	2008-01-16	Jubilant Organosys Limited	Process for the preparation of escitalopram or its acid addition salts

2006
- 2006-06-15 TW TW100102601A patent/TWI358407B/zh not_active IP Right Cessation
- 2006-06-15 TW TW095121358A patent/TWI347942B/zh not_active IP Right Cessation
- 2006-06-21 AR ARP060102654A patent/AR055062A1/es not_active Application Discontinuation
- 2006-06-21 MY MYPI2010000618A patent/MY143239A/en unknown
- 2006-06-21 MY MYPI20062933A patent/MY143252A/en unknown
- 2006-06-22 EP EP10179395A patent/EP2325177A1/en not_active Withdrawn
- 2006-06-22 HR HRP20110093TT patent/HRP20110093T4/hr unknown
- 2006-06-22 FI FI20080548A patent/FI20080548L/fi unknown
- 2006-06-22 EA EA201001108A patent/EA201001108A1/ru unknown
- 2006-06-22 KR KR1020117005777A patent/KR101340815B1/ko not_active Expired - Lifetime
- 2006-06-22 CA CA2612827A patent/CA2612827C/en not_active Expired - Fee Related
- 2006-06-22 ES ES06742481.2T patent/ES2356838T5/es not_active Expired - Lifetime
- 2006-06-22 ES ES200750085A patent/ES2319073B1/es not_active Expired - Fee Related
- 2006-06-22 BR BRPI0612295-7A patent/BRPI0612295A2/pt not_active IP Right Cessation
- 2006-06-22 TR TR2007/08792T patent/TR200708792T1/xx unknown
- 2006-06-22 FI FI20077133A patent/FI20077133L/fi unknown
- 2006-06-22 CZ CZ20080429A patent/CZ301286B6/cs not_active IP Right Cessation
- 2006-06-22 AT AT0900506U patent/AT10983U1/de not_active IP Right Cessation
- 2006-06-22 CN CN201010286088XA patent/CN101928269A/zh active Pending
- 2006-06-22 EA EA200800102A patent/EA019239B1/ru not_active IP Right Cessation
- 2006-06-22 SI SI200630923T patent/SI1896439T2/sl unknown
- 2006-06-22 DE DE112006001619T patent/DE112006001619T5/de not_active Withdrawn
- 2006-06-22 ZA ZA200711066A patent/ZA200711066B/xx unknown
- 2006-06-22 SG SG201100648-3A patent/SG169358A1/en unknown
- 2006-06-22 CN CNA2006800200393A patent/CN101189220A/zh active Pending
- 2006-06-22 PL PL06742481T patent/PL1896439T5/pl unknown
- 2006-06-22 EP EP10179318A patent/EP2385044A1/en not_active Withdrawn
- 2006-06-22 PL PL384185A patent/PL384185A1/pl unknown
- 2006-06-22 KR KR1020127014205A patent/KR20120064140A/ko not_active Ceased
- 2006-06-22 CZ CZ20070898A patent/CZ299906B6/cs not_active IP Right Cessation
- 2006-06-22 EP EP06742481.2A patent/EP1896439B2/en not_active Expired - Lifetime
- 2006-06-22 KR KR1020077028918A patent/KR20080018191A/ko not_active Ceased
- 2006-06-22 WO PCT/DK2006/000366 patent/WO2006136169A2/en not_active Ceased
- 2006-06-22 KR KR1020117015711A patent/KR20110084341A/ko not_active Ceased
- 2006-06-22 DE DE602006019961T patent/DE602006019961D1/de not_active Expired - Lifetime
- 2006-06-22 CA CA002646780A patent/CA2646780A1/en not_active Abandoned
- 2006-06-22 SK SK50040-2007A patent/SK500402007A3/sk unknown
- 2006-06-22 AU AU2006261452A patent/AU2006261452B2/en not_active Withdrawn - After Issue
- 2006-06-22 JP JP2008517323A patent/JP4906852B2/ja not_active Expired - Lifetime
- 2006-06-22 RS RS20110057A patent/RS51575B2/sr unknown
- 2006-06-22 PT PT06742481T patent/PT1896439E/pt unknown
- 2006-06-22 HU HU0800135A patent/HUP0800135A3/hu unknown
- 2006-06-22 CZ CZ20080430A patent/CZ300686B6/cs not_active IP Right Cessation
- 2006-06-22 AT AT06742481T patent/ATE497500T1/de active
- 2006-06-22 EE EEU200800003U patent/EE00773U1/xx not_active IP Right Cessation
- 2006-06-22 KR KR1020107026804A patent/KR20100133023A/ko not_active Ceased
- 2006-06-22 DK DK06742481.2T patent/DK1896439T4/en active
- 2006-06-22 GB GB0811164A patent/GB2448834B/en not_active Expired - Fee Related
- 2006-06-22 UA UAA200800362A patent/UA86536C2/ru unknown
- 2006-06-22 GB GB0724557A patent/GB2442160B/en not_active Expired - Fee Related
- 2006-06-22 MX MX2007015328A patent/MX2007015328A/es active IP Right Grant
- 2006-06-22 TR TR2010/00625T patent/TR201000625T1/xx unknown
2007
- 2007-11-18 IL IL187454A patent/IL187454A0/en unknown
- 2007-12-19 BG BG10110024A patent/BG66086B1/bg unknown
- 2007-12-21 LV LVP-07-157A patent/LV13677B/lv unknown
2008
- 2008-01-14 IS IS8705A patent/IS8705A/is unknown
- 2008-01-18 NO NO20080359A patent/NO20080359L/no unknown
- 2008-01-21 LT LT2008005A patent/LT5550B/lt not_active IP Right Cessation
- 2008-01-21 DK DK200800075A patent/DK200800075A/da not_active Application Discontinuation
- 2008-10-07 JP JP2008260742A patent/JP4415056B2/ja not_active Expired - Lifetime
2009
- 2009-02-27 DK DKPA200900284A patent/DK200900284A/da not_active Application Discontinuation
- 2009-03-10 ZA ZA200901698A patent/ZA200901698B/en unknown
- 2009-05-12 JP JP2009115280A patent/JP2009179635A/ja active Pending
- 2009-05-12 JP JP2009115279A patent/JP2009179634A/ja active Pending
- 2009-07-07 AT AT0041709U patent/AT11883U1/de not_active IP Right Cessation
2010
- 2010-03-05 AU AU2010200844A patent/AU2010200844A1/en not_active Withdrawn
- 2010-12-20 NO NO20101777A patent/NO20101777L/no not_active Application Discontinuation
- 2010-12-27 AR ARP100104958A patent/AR079750A2/es not_active Application Discontinuation
2011
- 2011-02-03 CY CY20111100116T patent/CY1112392T1/el unknown
- 2011-11-24 JP JP2011255804A patent/JP5731957B2/ja not_active Expired - Lifetime

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4943590A (en)	1988-06-14	1990-07-24	H. Lundbeck A/S	Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydrosobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof
WO2004056791A1 (en)	2002-12-23	2004-07-08	H. Lundbeck A/S	Escitalopram hydrobromide and a method for the preparation thereof
WO2005018617A1 (en)	2003-08-19	2005-03-03	Wyeth	Fast dissolving tablet

Also Published As

Publication number	Publication date
PT1896439E (pt)	2011-02-15
HRP20110093T1 (hr)	2011-03-31
AU2010200844A1 (en)	2010-04-01
JP4415056B2 (ja)	2010-02-17
LV13677B (en)	2008-05-20
EP1896439B1 (en)	2011-02-02
JP5731957B2 (ja)	2015-06-10
MX2007015328A (es)	2008-02-15
SI1896439T2 (sl)	2014-12-31
TR201000625T1 (tr)	2010-03-22
EA019239B1 (ru)	2014-02-28
CN101189220A (zh)	2008-05-28
DE602006019961D1 (de)	2011-03-17
FI20080548A7 (fi)	2008-10-07
AU2006261452B2 (en)	2010-02-04
TR200708792T1 (tr)	2008-05-21
AR079750A2 (es)	2012-02-15
CN101928269A (zh)	2010-12-29
ES2356838T3 (es)	2011-04-13
EP2325177A1 (en)	2011-05-25
MY143239A (en)	2011-04-15
KR20110084341A (ko)	2011-07-21
AU2006261452A1 (en)	2006-12-28
CA2612827C (en)	2010-11-30
BG66086B1 (bg)	2011-03-31
JP2008546724A (ja)	2008-12-25
ES2319073B1 (es)	2010-02-26
CA2612827A1 (en)	2006-12-28
UA86536C2 (ru)	2009-04-27
ZA200901698B (en)	2010-04-28
GB2448834A (en)	2008-10-29
SG169358A1 (en)	2011-03-30
CZ299906B6 (cs)	2008-12-29
DK200800075A (da)	2008-03-15
KR20120064140A (ko)	2012-06-18
PL1896439T3 (pl)	2011-04-29
EP1896439A2 (en)	2008-03-12
JP2012072168A (ja)	2012-04-12
AT10983U1 (de)	2010-02-15
EA201001108A1 (ru)	2011-02-28
GB2442160A (en)	2008-03-26
TWI358407B (en)	2012-02-21
SK500402007A3 (sk)	2008-05-06
DK200900284A (da)	2009-02-27
CZ2007898A3 (cs)	2008-01-23
AR055062A1 (es)	2007-08-01
NO20101777L (no)	2008-01-18
EA200800102A1 (ru)	2008-04-28
SI1896439T1 (sl)	2011-03-31
FI20077133A7 (fi)	2007-12-20
WO2006136169A2 (en)	2006-12-28
RS51575B (sr)	2011-08-31
GB2448834B (en)	2010-01-20
KR20100133023A (ko)	2010-12-20
RS51575B2 (sr)	2018-02-28
GB0724557D0 (en)	2008-01-23
AT11883U1 (de)	2011-06-15
CA2646780A1 (en)	2006-12-28
TW200740785A (en)	2007-11-01
FI20077133L (fi)	2007-12-20
DK1896439T4 (en)	2015-01-12
TW201130808A (en)	2011-09-16
FI20080548L (fi)	2008-10-07
KR20080018191A (ko)	2008-02-27
HUP0800135A2 (en)	2008-06-30
CY1112392T1 (el)	2015-12-09
EE00773U1 (et)	2008-10-15
ES2319073A1 (es)	2009-05-01
TWI347942B (en)	2011-09-01
MY143252A (en)	2011-04-15
LT2008005A (en)	2008-10-27
HRP20110093T4 (hr)	2015-02-27
BG110024A (bg)	2008-05-30
GB0811164D0 (en)	2008-07-23
CZ300686B6 (cs)	2009-07-15
GB2442160B (en)	2010-01-20
EP1896439B2 (en)	2014-10-15
PL1896439T5 (pl)	2016-01-29
IS8705A (is)	2008-01-14
JP2009046506A (ja)	2009-03-05
DK1896439T3 (da)	2011-02-28
ZA200711066B (en)	2009-07-29
NO20080359L (no)	2008-01-18
IL187454A0 (en)	2008-02-09
CZ301286B6 (cs)	2009-12-30
DE112006001619T5 (de)	2008-06-12
WO2006136169A3 (en)	2007-10-18
KR20110033310A (ko)	2011-03-30
JP2009179635A (ja)	2009-08-13
PL384185A1 (pl)	2008-06-23
ES2356838T5 (es)	2015-01-26
EP2385044A1 (en)	2011-11-09
HUP0800135A3 (en)	2009-01-28
JP4906852B2 (ja)	2012-03-28
KR101340815B1 (ko)	2013-12-11
BRPI0612295A2 (pt)	2011-01-04
JP2009179634A (ja)	2009-08-13
ATE497500T1 (de)	2011-02-15

Legal Events

Date	Code	Title	Description
2012-01-25	MM9A	Lapsed patents	Effective date: 20110622

Publication	Publication Date	Title
JP5731957B2 (ja)	2015-06-10	エスシタロプラムの結晶質塩基、およびエスシタロプラム塩基を含む口腔内分散性錠剤
US7560576B2 (en)	2009-07-14	Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
HK1121136A (en)	2009-04-17	Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
HK1147249A (en)	2011-08-05	Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base